Pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable Threonine Tyrosine Kinase (TTK) inhibitors

Minhao Huang,Yongjun Huang,Jing Guo,Lei Yu,Yu Chang,Xiaolu Wang,Jinfeng Luo,Yanhui Huang,Zhengchao Tu,Xiaoyun Lu,Yong Xu,Zhimin Zhang,Zhang Zhang,Ke Ding
DOI: https://doi.org/10.1016/j.ejmech.2020.113023
IF: 7.088
2021-02-01
European Journal of Medicinal Chemistry
Abstract:A series of pyrido [2, 3-d]pyrimidin-7(8H)-ones were designed and synthesized as new selective orally bioavailable Threonine Tyrosine Kinase (TTK) inhibitors. One of the representative compounds, 5o, exhibited strong binding affinity with a K<sub>d</sub> value of 0.15 nM, but was significantly less potent against a panel of 402 wild-type kinases at 100 nM. The compound also potently inhibited the kinase activity of TTK with an IC<sub>50</sub> value of 23 nM, induced chromosome missegregation and aneuploidy, and suppressed proliferation of a panel of human cancer cell lines with low μM IC<sub>50</sub> values. Compound 5o demonstrated good oral pharmacokinetic properties with a bioavailability value of 45.3% when administered at a dose of 25 mg/kg in rats. Moreover, a combination therapy of 5o with paclitaxel displayed promising in vivo efficacy against the HCT-116 human colon cancer xenograft model in nude mice with a Tumor Growth Inhibition (TGI) value of 78%. Inhibitor 5o may provide a new research tool for further validating therapeutic potential of TTK inhibition.
chemistry, medicinal
What problem does this paper attempt to address?